Bictegravir/lenacapavir (Bixlenvo) vs Islatravir/lenacapavir
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV capsid · full HIV pipeline
Bictegravir/lenacapavir (Bixlenvo)
Marketed by Gilead Sciences
NCT05502341 · Phase 2/3 · active, not recruiting
This was a randomized, active-controlled trial in 557 people in its Phase 3 part, but it was open-label, so participants and investigators knew which treatment each person received. Its primary endpoint, the proportion with detectable HIV-1 RNA at week 48, is an objective laboratory measure, and bictegravir/lenacapavir met the non-inferiority goal against continued complex regimens.
Next expected readout: July 2028 · NCT07908446 (registry estimate)
Reported efficacy
Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm; Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). (met)
Result source: NCT05502341
Islatravir/lenacapavir
Developed by Gilead Sciences and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bictegravir/lenacapavir (Bixlenvo) | Islatravir/lenacapavir |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Trial running · NCT06532656 | —Trial running · NCT06630286 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Trial running · NCT06532656 | —Trial running · NCT06630286 |
| CD4 count, change (week 48) | —Trial running · NCT06532656 | —Trial running · NCT06630286 |
HIV-1 RNA below 50 copies/mL (week 48)
- Bictegravir/lenacapavir (Bixlenvo)
- —Trial running · NCT06532656
- Islatravir/lenacapavir
- —Trial running · NCT06630286
HIV-1 RNA 50 copies/mL or more (week 48)
- Bictegravir/lenacapavir (Bixlenvo)
- —Trial running · NCT06532656
- Islatravir/lenacapavir
- —Trial running · NCT06630286
CD4 count, change (week 48)
- Bictegravir/lenacapavir (Bixlenvo)
- —Trial running · NCT06532656
- Islatravir/lenacapavir
- —Trial running · NCT06630286
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Islatravir/lenacapavir: no structured comparison results are available for HIV.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir/lenacapavir (Bixlenvo)'s landscape · Islatravir/lenacapavir's landscape